ArticleThe Lancet regional health. Europe2025
Trends in epilepsy mortality of three incidence cohorts across 2006-2023 in Sweden: a matched register-based study.
Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical application of artificial intelligence technology in epilepsy.Acta epileptologica · 2026Review
- Differences in Survival Associated With the First Antiseizure Medication in People With Dementia and Epilepsy.Neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Idiopathic epilepsy alone accounts for a large health burden as shown in the Global Burden of Diseases Study. In countries with ageing populations, secondary epilepsies are now even more common. Altered clinical practice and reduced use of older enzyme-inducing drugs may be beneficial, but understanding of trends in the prognosis of all epilepsy is needed. Our objective was to determine and study trends in mortality in persons with epilepsy in Sweden through 2006-2023. Methods: We performed a matched cohort study by cross-referencing National Patient, Drug, and Cause of Death Registers. We included all persons with a diagnosis of epilepsy and antiseizure medication (ASM) after 2006 (n = 61,375) and three age-/sex-matched comparators/case. Mortality was assessed for three incidence cohorts; 2006-2010, 2011-2015, and 2016-2020, totally and in four subgroups: age >50, vascular disease, generalized epilepsy, and age <20. Risk of death was assessed by Cox regression. Findings: Carbamazepine and valproic acid were common first ASMs in 2006-2010, but replaced by levetiracetam by 2016-2020. Valproate became less common in generalized epilepsy. The adjusted hazard ratio [HR] for death was 1.99 (95% confidence interval [CI]:1.90-2.08) in 2006-2010 and 1.90 (95% CI: 1.82-1.99) in 2016-2020. The adjusted HR for death was 1.59 (95% CI: 1.50-1.68) for persons with cardiovascular disease versus comparators during 2016-2020. A sensitivity analysis showed that the excces risk of cardiovascular death had decreased between our cohorts. Young persons with epilepsy had a 30-50 fold increased HR of death. Dementia and vascular disease were important risk factors for death in persons with epilepsy. Interpretation: Mortality in epilepsy has remained largely unchanged relative to age- and sex matched comparators. The increased use of non-inducing ASMs may have reduced vascular risk slightly. Efforts should be targeted to specific patient groups, particularly regarding epilepsy management in the young and vascular and neurodegenerative comorbidities in older persons with epilepsy. Funding: Swedish Research Council, Swedish State through the ALF agreement, Knut and Ragnvi Jacobsson foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.